This has been shown to cause changes to the voice, including a rough or hoarse voice, reduced vocal range, and vocal fatigue
One study from 2013 followed 154 people with obesity or overweight who took metformin for six months
And this is something scientists are considering as they continue to monitor and study GLP-1s and their effects
For most people, the side effects are quite mild and temporary
We discuss: Medicare Bridge Program eligibility requirements Zepbound, Wegovy, Foundayo (orforglipron), and GLP-1 coverage updates BMI and comorbidity qualifications Prediabetes, sleep apnea, cardiovascular disease, and obesity treatment access How Medicare patients can obtain GLP-1 medications Why obesity is finally being treated as a chronic disease The future of obesity medicine and Medicare coverage Concerns about access to care vs access to medication Muscle loss, nutrition, strength training, and healthy weight loss The Treat and Reduce Obesity Act (TROA) This may be one of the most important developments in obesity treatment history, potentially opening the door for millions of Americans living with obesity, prediabetes, cardiovascular disease, and other weight-related conditions to receive evidence-based care
The Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines